Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study
Nannan Shi,Bin Liu,Ning Liang,Yan Ma,Youwen Ge,Honggang Yi,Hongmei Wo,Heng Gu,Yuan Kuang,Shaowen Tang,Yang Zhao,Lin Tong,Sihong Liu,Chen Zhao,Renbo Chen,Weiguo Bai,Yipin Fan,Zhan Shi,Li Li,Jia Liu,Hao Gu,Yingjie Zhi,Zhifei Wang,Yuanyuan Li,Huizhen Li,Jingya Wang,Liwen Jiao,Yaxin Tian,Yibai Xiong,Ruili Huo,Xiaohui Zhang,Jiangfeng Bai,Hong Chen,Liying Chen,Qiao Feng,Tuanmao Guo,Yong Hou,Guifen Hu,Xiaomei Hu,Yunhong Hu,Jin Huang,Qiuhua Huang,Shaozhen Huang,Liang Ji,Haihao Jin,Xiao Lei,Chunyan Li,Guihui Wu,Jike Li,Minqing Li,Quntang Li,Xianyong Li,Hongde Liu,Jinping Liu,Zhang Liu,Yuting Ma,Ya Mao,Liufen Mo,Hui Na,Jingwei Wang,Fangli Song,Sheng Sun,Dongting Wang,Mingxuan Wang,Xiaoyan Wang,Yinzhen Wang,Yudong Wang,Wei Wu,Lanping Wu,Yanhua Xiao,Haijun Xie,Hongming Xu,Shoufang Xu,Ruixia Xue,Chun Yang,Kaijun Yang,Puye Yang,Shengli Yuan,Gongqi Zhang,Jinbo Zhang,Linsong Zhang,Shusen Zhao,Wanying Zhao,Kai Zheng,Yingchun Zhou,Junteng Zhu,Tianqing Zhu,Guangxi Li,Wei Wang,Huamin Zhang,Yanping Wang,Yongyan Wang
DOI: https://doi.org/10.1016/j.phrs.2020.105290
IF: 10.334
2020-11-01
Pharmacological Research
Abstract:The coronavirus disease 2019 (COVID-19) epidemic has been almost controlled in China under a series of policies, including "early diagnosis and early treatment". This study aimed to explore the association between early treatment with Qingfei Paidu decoction (QFPDD) and favorable clinical outcomes. In this retrospective multicenter study, we included 782 patients (males, 56 %; median age 46) with confirmed COVID-19 from 54 hospitals in nine provinces of China, who were divided into four groups according to the treatment initiation time from the first date of onset of symptoms to the date of starting treatment with QFPDD. The primary outcome was time to recovery; days of viral shedding, duration of hospital stay, and course of the disease were also analyzed. Compared with treatment initiated after 3 weeks, early treatment with QFPDD after less than 1 week, 1-2 weeks, or 2-3 weeks had a higher likelihood of recovery, with adjusted hazard ratio (HR) (95 % confidence interval [CI]) of 3.81 (2.65-5.48), 2.63 (1.86-3.73), and 1.92 (1.34-2.75), respectively. The median course of the disease decreased from 34 days to 24 days, 21 days, and 18 days when treatment was administered early by a week (P < 0.0001). Treatment within a week was related to a decrease by 1-4 days in the median duration of hospital stay compared with late treatment (P<0.0001). In conclusion, early treatment with QFPDD may serve as an effective strategy in controlling the epidemic, as early treatment with QFPDD was associated with favorable outcomes, including faster recovery, shorter time to viral shedding, and a shorter duration of hospital stay. However, further multicenter, prospective studies with a larger sample size should be conducted to confirm the benefits of early treatment with QFPDD.
pharmacology & pharmacy